Latest Conference Articles

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

John Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia.

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.

Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.

Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.

Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.

Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.